Abstract:Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), has a central role in the coordination of receptor crosstalk and the integration of signaling pathways essential for neuronal differentiation, survival and function. This protein is a shared downstream effector for neurotrophin- and ephrin-receptors signaling that also interacts with the N-methyl-d-aspartate type of glutamate receptors (NMDARs). Failures in neurotrophic support and glutamate signaling are involved in pathologies related to excitotoxicity and/or neurodegeneration, where different components of these dynamic protein complexes result altered by a combination of mechanisms. In the case of Kidins220/ARMS, overactivation of NMDARs in excitotoxicity and cerebral ischemia triggers its downregulation, which contributes to neuronal death. This key role in neuronal life/death decisions encouraged us to investigate Kidins220/ARMS as a novel therapeutic target for neuroprotection. As the main mechanism of Kidins220/ARMS downregulation in excitotoxicity is proteolysis by calpain, we decided to develop cell-penetrating peptides (CPPs) that could result in neuroprotection by interference of this processing. To this aim, we first analyzed in detail Kidins220/ARMS cleavage produced in vitro and in vivo, identifying a major calpain processing site in its C-terminal region (between amino acids 1669 and 1670) within a sequence motif highly conserved in vertebrates. Then, we designed a 25-amino acids CPP (Tat-K) containing a short Kidins220/ARMS sequence enclosing the identified calpain site (amino acids 1668-1681) fused to the HIV-1 Tat protein basic domain, able to confer membrane permeability to attached cargoes. Transduction of cortical neurons with Tat-K reduced Kidins220/ARMS calpain processing in a dose- and time-dependent manner upon excitotoxic damage and allowed preservation of the activity of pERK1/2 and pCREB, signaling molecules central to neuronal survival and functioning. Importantly, these effects were associated to a significant increase in neuronal viability. This Kidins220/ARMS-derived peptide merits further research to develop novel neuroprotective therapies for excitotoxicity-associated pathologies.

An update on the therapeutic potential of calpain inhibitors: a patent review

Calpain Inhibitors as Potential Therapeutic Modulators in Neurodegenerative Diseases

Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space

Progress on Study of Calpain

Caspase inhibitors: a review on recently patented compounds (2016-2023)

Protein kinase C inhibitors: a patent review (2010 - present)

Efficient Large-Scale Synthesis of Cat811, A Potent Calpain Inhibitor of Interest in the Treatment of Cataracts

Revisiting the calpain hypothesis of learning and memory 40 years later

Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants.

Calpain as a Therapeutic Target for Hypoxic-Ischemic Encephalopathy

A Multifunctional Protease Inhibitor To Regulate Endolysosomal Function

Therapeutic cysteine protease inhibitors: a patent review (2018–present)

Patenting perspective of modulators of ClpP endopeptidase: 2019-present

Small-angle X-ray Scattering of Calpain-5 Reveals a Highly Open Conformation among Calpains.

Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity

Patent landscape highlighting therapeutic implications of peptides targeting myristoylated alanine-rich protein kinase-C substrate (MARCKS)

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

An updated patent review of Akt inhibitors (2016-present)

Recent Advances in the Development of Casein Kinase 1 Inhibitors

Calpain-1 and Calpain-2 in the Brain: New Evidence for a Critical Role of Calpain-2 in Neuronal Death

Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond